NVS—Helvea’s Olav Zilian projects Bexsero sales of $1.45B in 2016: http://www.bloomberg.com/news/2012-11-16/novartis-bexsero-meningitis-shot-wins-eu-agency-s-backing.html That’s probably the highest estimate out there from the sell side, but it’s not unreasonable, IMO.